+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates

  • ID: 2888016
  • Report
  • January 2020
  • Region: United Arab Emirates
  • 162 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates

Summary

The industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape -UAE”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the UAE. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape, and healthcare infrastructure of the UAE. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by a team of industry experts.

The UAE healthcare market is one of the major emerging markets in the world, with a strong focus on research and development (R&D). The UAE’s pharmaceutical market value in terms of US dollars was $1.51B in 2011 and increased at a CAGR of 13.2% to $2.20B in 2014. The market value is expected to increase further to $6.74B by 2023. The UAE medical device market was valued at $0.68B in 2015, which increased to $0.80B in 2018.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the UAE, and includes -
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Novartis, Pfizer, Roche, Sanofi, and Julphar) and profiles and SWOT analyses of the major players in the medical device market (Abbott, Medtronic, Philips Healthcare, GE Healthcare, and Siemens)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of UAE
  • Porter’s five forces analysis for pharmaceutical and medical devices market of UAE
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding the health-tech landscape of the country along with the major health-tech deals
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities and challenges to growth in the UAE healthcare market
Reasons to buy

The report will enhance your decision-making capability by allowing you to -
  • Develop business strategies by understanding the trends shaping and driving the UAE healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the UAE healthcare market
Note: Product cover images may vary from those shown
2 of 3
1 Executive Summary
1.1 Executive Summary - Overview
1.2 Key Highlights
1.3 Key Events: UAE Pharmaceutical History, 2012-2019
1.4 Healthcare Start-Ups in the UAE
1.5 Key Facts: UAE Pharmaceutical Market
1.6 Key Events: M&A, VF & PE Deals, Global Pharmaceutical Market, 2018-2019
1.7 Key Events: Mergers and Acquisitions
1.8 Country Profile, UAE, 2018

2 Overview of Pharmaceutical Market
2.1 Pharmaceutical Market - Overview
2.2 Pharmaceutical Market - Exports
2.3 Pharmaceutical Market - Imports
2.4 Pharmaceutical Market - Supply Channels
2.5 Pharmaceutical Market - Market Segments
2.6 Pharmaceutical Market - Major Therapeutic Classes
2.7 Pharmaceutical Market - Major Players

3 Overview of Medical Devices Market
3.1 Medical Device Market - Overview
3.2 Medical Device Market -Major Segments
3.3 Medical Device Market - Diagnostics Market
3.4 Medical Device Market - Major Players

4 Pharmaceutical and Medical Device Market - Drivers and Barriers
4.1 Drivers
4.2 Barriers

5 Deal Analysis
5.1 Deal Analysis: M&A, VF and PE Deals, Pharmaceutical Market, UAE
5.2 Deal Analysis: M&A, VF and PE Deals, Medical Device Market, UAE

6 HealthTech Landscape
6.1 HealthTech Deals Landscape, UAE
6.1.1 Key HealthTech Deals, UAE
6.2 Adoption of Technology in Healthcare, UAE
6.3 Regulatory Scenario Covering Use of Technology in Healthcare, UAE

7 Pharmaceutical and Medical Device Market - Porter’s Five Forces Analysis
7.1 Pharmaceutical Market, UAE - Porter’s Five Forces Analysis
7.2 Medical Device Market, UAE - Porter’s Five Forces Analysis

8 Market Access
8.1 Overview of Healthcare System, UAE
8.2 Reimbursement of Medicinal Products, UAE
8.3 Overview of Health Insurance, UAE
8.3.1 Healthcare Spending and Health Price Index, UAE
8.3.2 Pricing Policies, UAE
8.4 Regulatory Landscape, UAE
8.4.1 Overview of Regulatory Agencies
8.4.2 Market Authorization for Pharmaceutical Products, UAE
8.4.3 Market Authorization for Medical Devices, UAE
8.4.4 Pharmaceutical Establishment Regulations, UAE
8.4.5 Exports and Imports, UAE
8.4.6 Intellectual Property Rights, Patent, UAE
8.4.7 Intellectual Property Rights, Trademark, UAE
8.4.8 Pharmaceutical Clinical Trials Landscape, UAE
8.4.9 Medical Devices Clinical Trials Landscape, UAE
8.4.10 Clinical Trial Regulations, UAE
8.4.11 Pharmaceutical Advertising Regulations, UAE
8.4.12 Labeling and Packaging Regulations, UAE

9 Country Healthcare Landscape
9.1 Healthcare Policy Highlights
9.2 Healthcare Facilities
9.3 Healthcare Parameters
9.4 Environmental Health
9.5 Healthcare Personnel
9.6 Disease Burden
9.7 Healthcare Expenditure

10 Trade Associations, UAE

11 Trade Fairs, UAE

12 Opportunities and Challenges

13 Appendix

List of Tables
Table 1: Pharmaceutical Market, UAE, Major Therapeutic Classes, 2017
Table 2: Medical Devices Market, UAE, Revenue by Segment
Table 3: Merger & Acquisition Deals, Medical Device Market, UAE, 2018-2019
Table 4: Insurance Providers, UAE, 2019
Table 5: Biosimilars Pricing, UAE, 2018
Table 6: Pharmaceutical Product Service Fees, UAE, 2019
Table 7: Medical Device Service Fees, UAE, 2019
Table 8: Pharmaceutical Establishment Service Fees, UAE, 2019
Table 9: Export Service Fees, UAE, 2019
Table 10: Patent Fees, UAE, 2019
Table 11: Advertisement Service Fees, UAE, 2019
Table 12: Label of a Pharmaceutical Product, UAE
Table 13: Minimum Particulars to Appear on Blisters or Strips, UAE
Table 14: Minimum Particulars to Appear on Small Immediate Packaging , UAE

List of Figures
Figure 1: Pharmaceutical Market Revenue ($B), UAE,2011-2018
Figure 2: Medical Device Market Revenue ($B), UAE, 2015-2020
Figure 3: Healthcare Startups, UAE, 2019
Figure 4: Number of Deals (2018-2019)
Figure 5: 2018-2019 Deal Overview By Region
Figure 6: Country Profile, UAE, 2018
Figure 7: Pharmaceutical Market, UAE, Revenue ($B), 2011-2018
Figure 8: Pharmaceutical Market, UAE, Revenue Forecast ($B), 2019-2023
Figure 9: Pharmaceutical Exports ($B), UAE, 2012-2018
Figure 10: Top Export Partners, UAE, 2018
Figure 11: Pharmaceutical Imports ($B), UAE, 2012-2018
Figure 12: Top Import Partners, UAE, 2018
Figure 13: Pharmaceutical Market, Supply Chain, UAE
Figure 14: Generics Market, UAE, 2017-2022
Figure 15: Biosimilar Licensing Procedure, UAE, 2019
Figure 16: OTC Market, UAE, Revenue ($M), 2011-2018
Figure 17: OTC Market by Drug Category, UAE, Revenue ($M), 2018
Figure 18: Pharmaceutical Market, UAE, Major Therapeutic Classes, 2017
Figure 19: Medical Devices Market, UAE, Revenue ($B), 2015-2020
Figure 20: Medical Devices Market, UAE, Revenue Forecast ($B), 2021-2025
Figure 21: Medical Devices Market, UAE, Revenue by Segment ($M), 2018
Figure 22: In Vitro Diagnostics Market, UAE, Revenue ($M), 2015-2022
Figure 23: General Surgery Market, UAE, Revenue ($M), 2015-2022
Figure 24: Diagnostic Imaging Market, UAE, Revenue ($M), 2015-2022
Figure 25: Orthopedic Devices Market, UAE, Revenue ($M), 2015-2022
Figure 26: Neurology Devices Market, UAE, Revenue ($M), 2015-2022
Figure 27: Diagnostic Market, UAE, Revenue ($M), 2015-2020
Figure 28: Diagnostic Market, UAE, Revenue Forecast ($M), 2021-2025
Figure 29: Medical Device Market, UAE, Revenue of Major Companies ($B), 2018
Figure 30: Deal Value and Deal Count, Pharmaceutical Market, UAE, 2018-2019
Figure 31: Deal Value and Deal Count, by Quarter, Pharmaceutical Market, UAE, 2018-2019
Figure 32: Top Therapy Areas by Deal Value, Pharmaceutical Market, UAE, 2018-2019
Figure 33: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, UAE, 2018-2019
Figure 34: Deal Count, HealthTech, UAE, 2018-2019
Figure 35: Healthcare System, UAE, 2019
Figure 36: Drug Formulary Application Requirements, UAE
Figure 37: Formulary Application Procedure and Processing, UAE
Figure 38: MOHAP Formulary Smart Application, UAE
Figure 39: Issue of a Health Card, UAE
Figure 40: OOP Expenditure (% of total expenditure on health), UAE, 2011-2016
Figure 41: Annual Rate of Change (%), Health Price Index, UAE, 2011-2018
Figure 42: Product Pricing Certificate, UAE, 2019
Figure 43: MOHAP, Organizational Structure, UAE, 2019
Figure 44: HAAD, Organizational Structure, UAE, 2019
Figure 45: Requirements for Pharmaceutical Products Registration, UAE, 2019
Figure 46: Process of Pharmaceutical Products Registration, UAE, 2019
Figure 47: Requirements for Medical Device Registration, UAE, 2019
Figure 48: Process of Medical Device Registration, UAE, 2019
Figure 49: Requirements for Pharmaceutical Establishment Registration, UAE, 2019
Figure 50: Process of Pharmaceutical Establishment Licensing, UAE, 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
The UAE's healthcare market has significant potential for growth, driven by an increasing burden of lifestyle-related diseases, medical tourism, straightforward regulatory guidelines and a preference for branded imported products. However, factors such as frequent price cuts by the government and usage of counterfeit drugs will restrict the growth of the pharmaceutical market.

The UAE is the second largest country in the Middle East in terms of capital invested in the pharmaceutical sector. In 2013, the UAE's pharmaceutical market was estimated to be worth $2.4 billion, having increased from $1.3 billion in 2008 at a Compound Annual Growth Rate (CAGR) of 12.6%. The market is expected to reach $3.7 billion in 2020 at a CAGR of 5.3% (Kulkarni, 2010). Increased healthcare expenditure, the growing popularity of medical tourism and a growing elderly population are the main contributors to market growth.

Due to its growing healthcare infrastructure and lower treatment costs compared to competitors, the UAE is quickly gaining popularity as a medical tourism destination due to its low costs, English-speaking medical staff and virtually non-existent queues for treatment (Woodman, 2012). Dubai Health Authority is working to develop the medical tourism sector. It is formulating different healthcare packages according to patient requirements and the first package (wellness and preventive services package) is to be launched in October 2014 (UAEinteract, 2014f).

Branded imported drugs dominate the pharmaceutical market, with approximately 80% of the market share. Therapeutic segments such as cardiovascular diseases and cancer are expected to grow significantly in the coming years due to the growing incidence of certain lifestyle diseases. Multinational companies will continue to penetrate the market as they offer largely patented drugs, whereas a lack of R&D activities from domestic manufacturers has limited their ability to offer patented drugs.

The UAE government has been reducing the prices of drugs since 2011 to make them more affordable for people as the prices of pharmaceutical medicines were comparatively much higher than in other neighboring GCC countries. Since 2011, the Ministry of Health (MoH) has reduced the prices of medicines five times, by percentages ranging from 1% to 60% (Sophia, 2014; Zain, 2014).

The proliferation of counterfeit drugs in the UAE is very high. According to a 2010 European Commission report, 73% of the drugs seized in the European Union (EU) were routed through the UAE (Underwood, 2010). These factors hamper the pharmaceutical market in the UAE.

In 2008, the UAE's medical device market was valued at approximately $600.2m and $733.3m in 2013. The medical device market is estimated to reach $978.9m in 2020, at a CAGR of 4.2% from 2014, mainly due to positive demographics, increased healthcare awareness and a rise in healthcare spending. The significant demand for medical devices in the UAE is met through imports.

In an attempt to prevent age-related chronic diseases and lifestyle diseases, the government has implemented the national Weqaya program and set up various specialty healthcare facilities.
Note: Product cover images may vary from those shown
Adroll
adroll